What is the current valuation of the China radiopharmaceuticals market?

As of 2024, the market valuation was 0.532 USD Billion. Read More

What is the projected market size for the China radiopharmaceuticals market by 2035?

The market is expected to reach a valuation of 1.27 USD Billion by 2035. Read More

What is the expected CAGR for the China radiopharmaceuticals market during the forecast period?

The anticipated CAGR for the market from 2025 to 2035 is 8.26%. Read More

Which applications are driving growth in the China radiopharmaceuticals market?

Key applications include Oncology, Cardiology, Neurology, Thyroid Imaging, and Infection Imaging, with Oncology projected to grow from 0.25 to 0.55 USD Billion. Read More

What are the primary end-use segments in the China radiopharmaceuticals market?

The main end-use segments are Hospitals, Diagnostic Imaging Centers, Research Laboratories, and Nuclear Medicine Clinics, with Hospitals expected to grow from 0.213 to 0.5 USD Billion. Read More

What types of radiopharmaceuticals are available in the China market?

The market includes Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals, Radioisotopes, and Radiolabeled Compounds, with Diagnostic Radiopharmaceuticals projected to increase from 0.2 to 0.45 USD Billion. Read More

How are radiopharmaceuticals distributed in China?

Distribution channels include Direct Sales, Distributors, and Online Sales, with Direct Sales expected to grow from 0.213 to 0.487 USD Billion. Read More

What is the significance of research laboratories in the China radiopharmaceuticals market?

Research Laboratories are crucial, with their market size projected to grow from 0.106 to 0.25 USD Billion. Read More

How does the growth of the China radiopharmaceuticals market compare to other regions?

While specific regional comparisons are not provided, the projected growth rate of 8.26% suggests a robust expansion in the China radiopharmaceuticals market. Read More

China Radiopharmaceuticals Market

Q: Who are the key players in the China radiopharmaceuticals market?

Prominent players include China Isotope & Radiation Corporation, Shanghai United Imaging Healthcare, and Siemens Healthineers, among others. Read More

ID: MRFR/Pharma/42171-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

China Radiopharmaceuticals Market Research Report By Type (Diagnostic, Therapeutic) and By Application (Neurology, Cardiology, Oncology, Others) - Growth & Industry Forecast 2025 To 2035

China Radiopharmaceuticals Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)8.26%

2024 Market Size$ 0.53 Billion

2025 Market Size$ 0.58 Billion

2035 Market Size$ 1.27 Billion

Key Players

China Isotope & Radiation Corporation

Shanghai United Imaging Healthcare Co Ltd

Beijing Huayi Isotopes Co Ltd

Nanjing Jintan Pharmaceutical Co Ltd

Shenzhen BGI Genomics Co Ltd

Siemens Healthineers

Trends

Technological Advancements
Regulatory Developments
Growing Demand for Diagnostics

Opportunities

Increasing Incidence of Cancer
Government Initiatives and Funding
Aging Population and Healthcare Needs

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Neurology
  4. 4.1.4 Thyroid Imaging
  5. 4.1.5 Infection Imaging
2. 4.2 Healthcare, BY End Use (USD Billion)
  1. 4.2.1 Hospitals
  2. 4.2.2 Diagnostic Imaging Centers
  3. 4.2.3 Research Laboratories
  4. 4.2.4 Nuclear Medicine Clinics
3. 4.3 Healthcare, BY Type of Radiopharmaceutical (USD Billion)
  1. 4.3.1 Diagnostic Radiopharmaceuticals
  2. 4.3.2 Therapeutic Radiopharmaceuticals
  3. 4.3.3 Radioisotopes
  4. 4.3.4 Radiolabeled Compounds
4. 4.4 Healthcare, BY Distribution Channel (USD Billion)
  1. 4.4.1 Direct Sales
  2. 4.4.2 Distributors
  3. 4.4.3 Online Sales
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 China Isotope & Radiation Corporation (CN)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Shanghai United Imaging Healthcare Co Ltd (CN)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Beijing Huayi Isotopes Co Ltd (CN)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Nanjing Jintan Pharmaceutical Co Ltd (CN)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Shenzhen BGI Genomics Co Ltd (CN)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Siemens Healthineers (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 GE Healthcare (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Philips Healthcare (NL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY APPLICATION
3. 6.3 CHINA MARKET ANALYSIS BY END USE
4. 6.4 CHINA MARKET ANALYSIS BY TYPE OF RADIOPHARMACEUTICAL
5. 6.5 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
14. 6.14 HEALTHCARE, BY END USE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
16. 6.16 HEALTHCARE, BY TYPE OF RADIOPHARMACEUTICAL, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY TYPE OF RADIOPHARMACEUTICAL, 2024 TO 2035 (USD Billion)
18. 6.18 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY END USE, 2026-2035 (USD Billion)
  3. 7.2.3 BY TYPE OF RADIOPHARMACEUTICAL, 2026-2035 (USD Billion)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Radiopharmaceuticals Market Segmentation

China Radiopharmaceuticals Market By Application (USD Billion, 2026-2035)

Oncology
Cardiology
Neurology
Thyroid Imaging
Infection Imaging

China Radiopharmaceuticals Market By End Use (USD Billion, 2026-2035)

Hospitals
Diagnostic Imaging Centers
Research Laboratories
Nuclear Medicine Clinics

China Radiopharmaceuticals Market By Type of Radiopharmaceutical (USD Billion, 2026-2035)

Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Radioisotopes
Radiolabeled Compounds

China Radiopharmaceuticals Market By Distribution Channel (USD Billion, 2026-2035)

Direct Sales
Distributors
Online Sales

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”